ArticleCancers2020
CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 63 citations in OpenAlex.
- Double-coated PLGA nanoparticles with hierarchical surface architecture for CD44-targeted siRNA delivery.Drug delivery and translational research · 2026Article
- The role of stem cells in the pharmacological assessment of nanoparticles.Journal of pharmaceutical analysis · 2026Review
- Photodynamic Therapy-Based Strategies Targeted at Cancer Stem Cells: A Scoping Review.Cancers · 2026Review
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- Non-Cytotoxic Photodynamic Therapy with Talaporfin Sodium Reduces the Expression of CXCR4 and Enhances Chemotherapeutic Efficacy in Undifferentiated Gastric Cancer Cell Line HGC27.Acta histochemica et cytochemica · 2025Article
- Breaking the Resistance: Photodynamic Therapy in Cancer Stem Cell-Driven Tumorigenesis.Pharmaceutics · 2025Review
- Cancer stem cell specificity as new targets in breast tumor treatment.Oncology research · 2025Review
- Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches.Journal of translational medicine · 2024Review
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.Medical oncology (Northwood, London, England) · 2024Review
- Novel PEGylated cholephytosomes for targeting fisetin to breast cancer: in vitro appraisal and in vivo antitumoral studies.Drug delivery and translational research · 2024Article
- Edge advances in nanodrug therapies for osteoarthritis treatment.Frontiers in pharmacology · 2024Review
- A polymeric nanocarrier that eradicates breast cancer stem cells and delivers chemotherapeutic drugs.Biomaterials research · 2023Article
- Photodynamic therapy in cancer stem cells - state of the art.Lasers in medical science · 2023Review
- Photosensitizers-Loaded Nanocarriers for Enhancement of Photodynamic Therapy in Melanoma Treatment.Pharmaceutics · 2023Review
- Mesenchymal Stem Cell Membrane-Coated TPCSPharmaceutics · 2023Article
- Combining β-Carotene with 5-FU via Polymeric Nanoparticles as a Novel Therapeutic Strategy to Overcome uL3-Mediated Chemoresistance in p53-Deleted Colorectal Cancer Cells.Molecular pharmaceutics · 2023Article
- Inhibitory Effect and Mechanism of Ursolic Acid on Cisplatin-Induced Resistance and Stemness in Human Lung Cancer A549 Cells.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Co-Delivery of 8-Hydroxyquinoline Glycoconjugates and Doxorubicin by Supramolecular Hydrogel Based on α-Cyclodextrin and pH-Responsive Micelles for Enhanced Tumor Treatment.Pharmaceutics · 2022Article
- Novel Thieno [2,3-International journal of molecular sciences · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The presence of rare but highly tumorigenic cancer stem cells (CSCs) within the tumors is recognized as one of the major reasons of failure of conventional chemotherapies, mainly attributed to the development of drug resistance and increasing metastatic potential. Here, we propose a therapeutic strategy based on the simultaneous delivery of docetaxel (DTX) and the photosensitizer meso-tetraphenyl chlorine disulfonate (TPCS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.